Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s450. https://doi.org/10.25251/skin.8.supp.450